COMMUNIQUÉS West-GlobeNewswire

Better Choice Company Signs Memorandum of Understanding with Choom for Distribution Rights of CBD Animal Health Products in Canada
28/03/2019
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Better Choice Company, Inc (OTCQB: BTTR) (OTCQB: BTTRD) (the “Company”) is pleased to announce that it has signed a memorandum of understanding (“MOU”) with Choom Holdings [...]
OcellO announces two year agreement with Merus to provide in vitro research services for MCLA-158 and other undisclosed Biclonics® programs
28/03/2019
LEIDEN, the Netherlands, March 28, 2019 (GLOBE NEWSWIRE) -- OcellO B.V., a Contract Research Organisation offering 3D cell based assay services for drug discovery to the pharmaceutical industry, today announced that it [...]
OcellO annonce un accord de deux ans avec Merus pour assurer des services de recherche in vitro pour le programme MCLA-158 et d'autres programmes Biclonics® non divulgués
28/03/2019
LEIDEN, the Netherlands, 28 mars 2019 (GLOBE NEWSWIRE) -- OcellO B.V., organisme de recherche contractuelle offrant des services de dosage cellulaire 3D pour la découverte de médicaments à l'industrie pharmaceutique, a [...]
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development
28/03/2019
-- Stratifying Enrollment of MC4R Pathway Heterozygous (HET) Patients in Phase 2 Basket Study Based on Loss-of-Function (LOF) Variants -- -- Preliminary Data Show Consistent Weight Loss and Decreases in Hunger Observed [...]
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study
28/03/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today confirmed that the American [...]
Philips re-aligns its ‘Lives Improved’ target with the UN 2030 Sustainable Development Agenda following the completion of its portfolio transformation
28/03/2019
March 28, 2019 As of 2019, Philips will no longer include the contribution of Signify (formerly Philips Lighting) in its Lives Improved reporting Building on the 1.54 billion lives improved globally in 2018, Philips [...]
Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting
28/03/2019
LONDON, March 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of [...]
The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.
28/03/2019
The study (OAS-04-01) was a tolerance and pharmacokinetic study where the dose for Apealea (paclitaxel micellar) was determined. This phase I study was conducted at two clinics in Sweden located in Lund and Umeå between [...]
Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden
28/03/2019
Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden Herantis Pharma Plc Company release 28 March 2019 at 9:00 am Herantis Pharma Plc (“ [...]
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting
28/03/2019
COPENHAGEN, Denmark, March 28, 2019 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on Wednesday April 24 [...]
Santhera Provides Update on Filing for Conditional Marketing Authorization in Europe for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
28/03/2019
Pratteln, Switzerland, March 28, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces its intention to file an application for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) for the treatment of [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
28/03/2019
Regulated information Gosselies, Belgium, 28 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
28/03/2019
Information réglementée Gosselies, Belgique, le 28 mars 2019, 07h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux [...]
Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD
27/03/2019
ROCKVILLE, Md., March 27, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Precision BioSciences Announces Pricing of Initial Public Offering
27/03/2019
DURHAM, N.C., March 27, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, [...]
Genetically modified tequila bacterium produces cannabinoids from sugar: Farmako applies for a worldwide patent
27/03/2019
Standardized process for the production of cannabinoids First production of cannabinoids by biosynthesis without the use of yeast Production costs drop to one-thousandth of the previous costs FRANKFURT, Germany, March [...]
IntelGenx Grants Stock Options
27/03/2019
SAINT LAURENT, Quebec, March 27, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTC.QX:IGXT) announced today that the Company’s board of directors granted 100,000 [...]
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
27/03/2019
COPENHAGEN, Denmark, March 27, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced [...]
Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019
27/03/2019
TORONTO, March 27, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be [...]

Pages